Investor Presentaiton

EV obviously undervalued, showing great potentials for appreciation • The Company has maintained a ROE of around 14% for a long period of time. The share price of the Company as at • • • 26 August 2022 (HK$6.13) represented 0.52x 21A PB and 3.92x 21A PE, which is underestimated The average target price set by securities firms is around HK$12, reflecting an approximately 93% potential appreciation as compared to the share price (HK$6.13) as at 26 August 2022 Assuming the PB valuation of the Company remains unchanged, the annual ROE of over 14% can still offer an IRR of 14% for investors The values of equipment operation and hospital operation, which experienced rapid growth, have not yet been fully reflected in the market value of the Company ROE (%), 2021 P/B Great potentials for share price appreciation (HK$) 14.6 6.13 0.52x 2021 2022-8-26 34 =4 12.50 12.40 11.90 11.96 10.50 Closing price as at 26 August 2022 Target price stated in JPM April research report Target price stated in Citi July research report Target price report Target price Target price stated in DBS stated in UBS stated in GTJA October research August research April research report report Note: The above target prices are sourced from research reports of investment banks, and the average target price is calculated by the Company

View entire presentation